Financhill
Sell
37

ARCT Quote, Financials, Valuation and Earnings

Last price:
$13.14
Seasonality move :
4.53%
Day range:
$13.25 - $13.80
52-week range:
$8.04 - $25.88
Dividend yield:
0%
P/E ratio:
8.50x
P/S ratio:
2.74x
P/B ratio:
1.54x
Volume:
257.9K
Avg. volume:
505.6K
1-year change:
-42.53%
Market cap:
$361M
Revenue:
$138.4M
EPS (TTM):
-$2.53

Analysts' Opinion

  • Consensus Rating
    Arcturus Therapeutics Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $67.40, Arcturus Therapeutics Holdings has an estimated upside of 406.39% from its current price of $13.31.
  • Price Target Downside
    According to analysts, the lowest downside price target is $35.00 representing 100% downside risk from its current price of $13.31.

Fair Value

  • According to the consensus of 8 analysts, Arcturus Therapeutics Holdings has 406.39% upside to fair value with a price target of $67.40 per share.

ARCT vs. S&P 500

  • Over the past 5 trading days, Arcturus Therapeutics Holdings has underperformed the S&P 500 by -0.46% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Arcturus Therapeutics Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Arcturus Therapeutics Holdings revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Arcturus Therapeutics Holdings reported revenues of $25.5M.

Earnings Growth

  • Arcturus Therapeutics Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arcturus Therapeutics Holdings reported earnings per share of -$0.52.
Enterprise value:
159M
EV / Invested capital:
--
Price / LTM sales:
2.74x
EV / EBIT:
42.21x
EV / Revenue:
1.21x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-1.77x
Price / Operating cash flow:
76.35x
Enterprise value / EBITDA:
34.45x
Gross Profit (TTM):
--
Return On Assets:
-18.39%
Net Income Margin (TTM):
-51.96%
Return On Equity:
-27.08%
Return On Invested Capital:
-26.76%
Operating Margin:
-66.04%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $280.2M $110.6M $131.3M $32.6M $25.5M
Gross Profit -- -- -- -- --
Operating Income $77.3M -$123.4M -$82.1M -$30.4M -$16.8M
EBITDA $116.1M -$65.6M -$60.2M -$29.5M -$16M
Diluted EPS $4.15 -$3.91 -$2.53 -$1.00 -$0.52
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $470M $327M $424.6M $375.8M $278.8M
Total Assets $481.5M $342M $470.9M $418.8M $331.8M
Current Liabilities $53.3M $107.3M $90.1M $115.4M $49.4M
Total Liabilities $128.9M $157.2M $141.6M $154.9M $98M
Total Equity $352.6M $184.7M $329.2M $264M $233.8M
Total Debt $61.3M $63.5M -- -- $15M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations $45.2M $12.2M -$89.3M -$5.6M -$35.1M
Cash From Investing -$6.3M -$2.5M -$545K -$240K -$137K
Cash From Financing -$30.6M $5.5M $18.4M $2.2M $15.2M
Free Cash Flow $38.9M $9.8M -$89.9M -$5.8M -$35.3M
ARCT
Sector
Market Cap
$361M
$34.5M
Price % of 52-Week High
51.43%
49.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-42.53%
-35.15%
Beta (5-Year)
2.273
0.615
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $13.87
200-day SMA
Sell
Level $15.68
Bollinger Bands (100)
Buy
Level 10.85 - 14.81
Chaikin Money Flow
Sell
Level -64.5M
20-day SMA
Sell
Level $13.34
Relative Strength Index (RSI14)
Buy
Level 50.47
ADX Line
Buy
Level 27.4
Williams %R
Neutral
Level -70.3911
50-day SMA
Buy
Level $12.61
MACD (12, 26)
Buy
Level 0.38
25-day Aroon Oscillator
Buy
Level 64
On Balance Volume
Neutral
Level 64M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (1.3051)
Sell
CA Score (Annual)
Level (-0.4806)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (0.4462)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

Stock Forecast FAQ

In the current month, ARCT has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARCT average analyst price target in the past 3 months is $67.40.

  • Where Will Arcturus Therapeutics Holdings Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Arcturus Therapeutics Holdings share price will rise to $67.40 per share over the next 12 months.

  • What Do Analysts Say About Arcturus Therapeutics Holdings?

    Analysts are divided on their view about Arcturus Therapeutics Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arcturus Therapeutics Holdings is a Sell and believe this share price will drop from its current level to $35.00.

  • What Is Arcturus Therapeutics Holdings's Price Target?

    The price target for Arcturus Therapeutics Holdings over the next 1-year time period is forecast to be $67.40 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is ARCT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Arcturus Therapeutics Holdings is a Buy. 8 of 8 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ARCT?

    You can purchase shares of Arcturus Therapeutics Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arcturus Therapeutics Holdings shares.

  • What Is The Arcturus Therapeutics Holdings Share Price Today?

    Arcturus Therapeutics Holdings was last trading at $13.14 per share. This represents the most recent stock quote for Arcturus Therapeutics Holdings. Yesterday, Arcturus Therapeutics Holdings closed at $13.31 per share.

  • How To Buy Arcturus Therapeutics Holdings Stock Online?

    In order to purchase Arcturus Therapeutics Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

How High Can SharkNinja Stock Go?
How High Can SharkNinja Stock Go?

If you know popular consumer appliance brands Shark and Ninja,…

Will Oklo Stock Double?
Will Oklo Stock Double?

Oklo (NYSE: OKLO) is only a year removed from its SPAC‑enabled debut,…

Why a $5 Stock Is Suddenly a Cash Machine
Why a $5 Stock Is Suddenly a Cash Machine

If you stopped tracking Grab Holdings (NASDAQ: GRAB) after its 2021 SPAC…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
42
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Alerts

Buy
77
VBTX alert for Jul 15

Veritex Holdings [VBTX] is down 3.26% over the past day.

Buy
72
MNPR alert for Jul 15

Monopar Therapeutics [MNPR] is down 8.6% over the past day.

Buy
56
NBIS alert for Jul 15

Nebius Group NV [NBIS] is up 2.98% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock